IMSA WEATHERTECH SERIES
//
D:00
H:00
M:00
S:00
D:00
H:00
M:00
S:00
D:00
H:00
M:00
S:00
ZIONSVILLE, Ind. (June 18, 2024) – Rahal Letterman Lanigan Racing (RLL) announced today that Eurofarma, a Brazilian pharmaceutical company that is known for its commitment to investing in innovation and is present in 20 countries, will be primary sponsor of the No. 30 Honda-powered entry for Pietro Fittipaldi at the Firestone Grand Prix of Monterey, June 21-23. It is Fittipaldi’s first full season of NTT INDYCAR SERIES competition after having made nine starts in 2018 and 2021.
“I am very proud to race a blue and yellow, Eurofarma-branded Indy car,” said Pietro Fittipaldi. “Eurofarma has an immensely successful history in Brazilian Motorsports, and it is and honor to have them believe and support me in the INDYCAR SERIES.
“We are very happy to support a Brazilian driver in one of the biggest championships in the world and it is well aligned with our growth in the American market,” added Marco Billi, International CEO, at Eurofarma.
The 2024 NTT INDYCAR SERIES season resumes with the Firestone Grand Prix of Monterey on June 21-23. The race will be broadcast live on USA Network at 6:00 p.m. ET. All on-track action can be seen on NBC or NBC’s Peacock Premium streaming service or USA Network. For more information about the series or team, visit www.indycar.com and www.rahal.com.
About the Eurofarma Group
Eurofarma is a 100% Brazilian owned multinational company and, since 1972, has been recognized by the medical community and society for promoting broad access to health and quality of life through affordable health care, quality and innovation.
For more than 50 years, the Eurofarma Group has operated in the health sector by producing and commercializing products and services to improve people’s quality of life. It has diversified operations in all of the main segments, such as Medical Prescriptions, Over-the-Counter Drugs, Generic Drugs, Hospital Services and Oncological Care, in addition to exportation and drug production outsourcing. In Brazil alone, it offers more than 2k products, covering 42 medical specialties and more than 200 therapeutic classes. In addition to that, the corporation is the 1st most prescribed pharmaceutical company in Brazil.
The Eurofarma Group is present in 22 countries, covering 100% of the Latin American market. In 2023, it reported net sales amounting to R$ 9,1 billion, and today it employs more than 12 thousand collaborators.
